Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: A meta-analysis

  • Yang Z
  • Ye X
  • Zhu Y
 et al. 
  • 14


    Mendeley users who have this article in their library.
  • 2


    Citations of this article.


BACKGROUND: Adalimumab is used in an attempt to maintain remission for Ulcerative colitis. This study was to evaluate the efficacy and adverse events of adalimumab compared with placebo in inducing remission of Ulcerative colitis.

METHODS: MEDLINE, EMBASE, the Cochrane Controlled Trials Register, OVID, BIOSIS, CNKI, and Google were searched. All randomized trials comparing adalimumab with placebo in inducing remission of moderate-to-severe ulcerative colitis were included.

RESULTS: Two randomized controlled trials with a total of 754 participants met the inclusion criteria. The pooled risk ratio (RR) of clinical remission was 1.85 (95% confidence interval (CI) 1.26 to 2.72) following adalimumab treatment. RR of clinical response was 1.40 (95% CI 1.19 to 1.65) while that of mucosal healing was 1.23 (95% CI 1.03 to 1.47). RR of any adverse events was 1.00 (95% CI 0.93 to 1.09).

CONCLUSION: Compared with placebo, administration of adalimumab may increase the proportion of patients with moderate-to-severe ulcerative colitis attaining clinical remission, clinical response and mucosal healing. Adalimumab is also tolerated well in these patients.

Author-supplied keywords

  • Adalimumab
  • Efficacy
  • Meta-analysis
  • Safety
  • Ulcerative colitis

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • PUI: 602272172
  • PMID: 25784977
  • SCOPUS: 2-s2.0-84922965719
  • SGR: 84922965719
  • ISSN: 19405901
  • ISBN: 1940-5901


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free